| ［1］ |
向泓雨，刘荫华. 2022年《中华医学会乳腺外科临床实践指南》更新解读［J］. 中国肿瘤外科杂志，2022，14（3）：219-223.
|
| ［2］ |
王昭雨，姜军. 乳腺癌外科治疗理论和技术的发展与挑战［J/CD］.中华乳腺病杂志（电子版），2025，19（1）：1-5.
|
| ［3］ |
梁燕，姜军. 乳腺癌的区域外科治疗［J］. 中国普外基础与临床杂志，2019，26（12）：1398-1402.
|
| ［4］ |
Heil J，Kummel S，Schaefgen B，et al. Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques［J］. Br J Cancer，2015，113（11）：1565-1570.
|
| ［5］ |
van Loevezijn AA， van der Noordaa M， van Werkhoven ED， et al.Minimally Invasive complete response assessment of the breast after neoadjuvant systemic therapy for early breast cancer （MICRA trial）：interim analysis of a multicenter observational cohort study［J］. Ann Surg Oncol，2021，28（6）：3243-3253.
|
| ［6］ |
Tasoulis MK，Lee HB，Yang W，et al. Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict residual cancer［J］. JAMA Surg，2020，155（12）：e204103.
|
| ［7］ |
Pfob A，Sidey-GibbonsC，Rauch G，et al. Intelligent vacuum-assisted biopsy to identify breast cancer patients with pathologic complete response（ypT0 and ypN0）after neoadjuvant systemic treatment for omission of breast and axillary surgery［J］. J Clin Oncol，2022，40（17）：1903-1915.
|
| ［8］ |
Kuerer HM， Smith BD， Krishnamurthy S，et al. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy： a multicentre， single-arm， phase 2 trial［J］. Lancet Oncol，2022，23（12）：1517-1524.
|
| ［9］ |
Olagunju A，Forsman T，Ward RC. An update on the use of cryoablation and immunotherapy for breast cancer［J］. Front Immunol，2022，13：1026475.
|
| ［10］ |
Mcarthur HL，Diab A，Page DB，et al. A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling［J］. Clin Cancer Res，2016，22（23）：5729-5737.
|
| ［11］ |
Donker M，van Tienhoven G，Straver ME，et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer（EORTC 10981～22023 AMAROS）：a randomised，multicentre，open-label，phase 3 non-inferiority trial［J］. Lancet Oncol，2014，15（12）：1303-1310.
|
| ［12］ |
周文斌，谢晖，丁强，等. 微波消融在乳腺癌局部精准治疗中的新进展：联合免疫治疗未来可期［J］. 中国癌症杂志，2022，32（8）：698-704.
|
| ［13］ |
陈治光，何文，张巍. 乳腺癌的热消融治疗［J］. 中国医学影像学杂志，2023，31（12）：1332-1336.
|
| ［14］ |
Susini T，Nori J，Olivieri S，et al. Radiofrequency ablation for minimally invasive treatment of breast carcinoma：a pilot study in elderly inoperable patients［J］. Gynecol Oncol，2007，104（2）：304-310.
|
| ［15］ |
Yamamoto N，Fujimoto H，Nakamura R，et al. Pilot study of radiofrequency ablation therapy without surgical excision for T1 breast cancer：evaluation with MRI and vacuum-assisted core needle biopsy and safety management［J］. Breast Cancer，2011，18（1）：3-9.
|
| ［16］ |
Ito T，Oura S，Nagamine S，et al. Radiofrequency ablation of breast cancer：a retrospective study［J］. Clin Breast Cancer，2018，18（4）：e495-e500.
|
| ［17］ |
Kinoshita T. RFA experiences，indications and clinical outcomes［J］.Int J Clin Oncol，2019，24（6）：603-607.
|
| ［18］ |
Fine RE，Gilmore RC，Dietz JR，et al. Cryoablation without excision for low-risk early-stage breast cancer：3-year interim analysis of ipsilateral breast tumor recurrence in the ICE3 Trial［J］. Ann Surg Oncol，2021，28（10）：5525-5534.
|
| ［19］ |
Simmons RM，Ballman KV，Cox C，et al. A phase II trial exploring the success of cryoablation therapy in the treatment of invasive breast carcinoma：results from ACOSOG（Alliance）Z1072［J］. Ann Surg Oncol，2016，23（8）：2438-2445.
|
| ［20］ |
Toi M，Kinoshita T，Benson JR，et al. Non-surgical ablation for breast cancer：an emerging therapeutic option［J］. Lancet Oncol，2024，25（3）：e114-e125.
|
| ［21］ |
Giuliano AE，Ballman KV，Mccall L，et al. Effect of axillary dissection vs no axillary dissection on 10-Year overall survival among women with invasive breast cancer and sentinel node metastasis［J］. JAMA，2017，318（10）：918.
|
| ［22］ |
Galimberti V，Cole BF，Viale G，et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases （IBCSG 23-01）： 10-year follow-up of a randomised，controlled phase 3 trial［J］. Lancet Oncol，2018，19（10）：1385-1393.
|
| ［23］ |
Savolt A，Peley G，Polgar C，et al. Eight-year follow up result of the OTOASOR trial：the optimal treatment of the axilla-surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer： a randomized， single centre， phase Ⅲ， non-inferiority trial［J］. Eur J Surg Oncol，2017，43（4）：672-679.
|
| ［24］ |
Morrow M，Jagsi R，Mcleod MC，et al. Surgeon attitudes toward the omission of axillary dissection in early breast cancer［J］. JAMA Oncol，2018，4（11）：1511-1516.
|
| ［25］ |
Tinterri C，Gentile D，Gatzemeier W，et al. Preservation of axillary lymph nodes compared with complete dissection in T1-2 breast cancer patients presenting one or two metastatic sentinel lymph nodes：the SINODAR-ONE multicenter randomized clinical trial［J］. Ann Surg Oncol，2022，29（9）：5732-5744.
|
| ［26］ |
de Boniface J，Filtenborg TT，Ryden L，et al. Omitting axillary dissection in breast cancer with sentinel-node metastases［J］. N Engl J Med，2024，390（13）：1163-1175.
|
| ［27］ |
樊庆达，丛斌斌，陈玉光，等. 临床淋巴结阳性新辅助治疗后腋窝降阶处理的研究进展［J］. 中国癌症杂志，2023，33（2）：174-180.
|
| ［28］ |
中国抗癌协会乳腺癌专业委员会，中华医学会肿瘤学分会乳腺肿瘤学组. 中国抗癌协会乳腺癌诊治指南与规范（2024年版）［J］.中国癌症杂志，2023，33（12）：1092-1187.
|
| ［29］ |
Montagna G，Laws A，Ferrucci M，et al. Nodal burden and oncologic outcomes in patients with residual isolated tumor cells after neoadjuvant chemotherapy（ypN0i+）：the OPBC-05/ICARO Study［J］. J Clin Oncol，2024：JCO2401052.
|
| ［30］ |
Cabioglu N，Karanlik H，Yildirim N，et al. Favorable outcome with sentinel lymph node biopsy alone after neoadjuvant chemotherapy in clinically node positive breast cancer at diagnosis：turkish multicentric NEOSENTI-TURK MF-18-02-study［J］. Eur J Surg Oncol，2021，47（10）：2506-2514.
|
| ［31］ |
Agostinetto E，Caballero C，Ignatiadis M，et al. Axillary surgery for patients with residual isolated tumor cells（ypN0i+）after neoadjuvant systemic therapy for early breast cancer［J］. J Clin Oncol，2025，43（7）：771-775.
|
| ［32］ |
Almahariq MF，Levitin R，Quinn TJ，et al. Omission of axillary lymph node dissection is associated with inferior survival in breast cancer patients with residual N1 nodal disease following neoadjuvant chemotherapy［J］. Ann Surg Oncol，2021，28（2）：930-940.
|
| ［33］ |
邬思雨，李俊杰，邵志敏. 乳腺癌前哨淋巴结活组织检查术的发展历史及研究进展［J］. 中国癌症杂志，2023，33（6）：551-559.
|
| ［34］ |
Gentilini OD， Botteri E，Sangalli C，et al. Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes［J］. JAMA Oncol，2023，9（11）：1557.
|
| ［35］ |
Reimer T，Stachs A，Veselinovic K，et al. Axillary surgery in breast cancer-primary results of the INSEMA Trial［J］. N Engl J Med， 2025，392（11）：1051-1064.
|
| ［36］ |
Li J，Cheng J，Liu G，et al. Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer：a prospective phase II trial［J］. Cancer Biol Med，2022，19（7）：1100-1108.
|
| ［37］ |
Wintraecken VM，Boersma LJ，van Roozendaal LM，et al. Quality assurance of radiation therapy after breast-conserving surgery among patients in the BOOG 2013-08 trial［J］. Radiother Oncol，2024，191：110069.
|
| ［38］ |
Ryu JM，Lee HB， Ahn SH，et al. What to expect from the N0 axillary surgical treatment for lymph node-negative patients after ultrasonography ［NAUTILUS］trial （KBCSG-21）：clinicopathologic characteristics and axillary lymph node status of enrolled patients［J］.Cancer Res，84（9）： PS01-03.
|
| ［39］ |
Hersh EH， King TA. De-escalating axillary surgery in early-stage breast cancer［J］. Breast，2022， 62： S43-S49.
|